Palopegteriparatide for adults with chronic hypoparathyroidism: skeletal dynamics through 3 years of the phase 2 PaTH forward trial.

In 30 seconds

This randomized controlled trial evaluated the effects of palopegteriparatide in adults with chronic hypoparathyroidism over three years. The treatment allowed 91% of participants to discontinue conventional therapy while maintaining normal serum calcium levels. Although bone mineral density (BMD) decreased initially, mean Z-scores remained above zero at week 162, indicating sustained bone health.

Key findings

• 91% of participants achieved independence from conventional therapy by week 162.
• Mean BMD Z-scores remained above zero for all sites at week 162.
• Bone turnover markers peaked at weeks 12 and 26, then stabilized.
• Serum and urine calcium levels remained within normal ranges throughout the study.

Why it matters

The findings highlight the potential of palopegteriparatide to effectively manage chronic hypoparathyroidism by maintaining normal calcium levels and promoting bone health, which is crucial for preventing complications associated with the disease.